NCT02906345

Brief Summary

Therapeutic plasma exchange (TPE) should used for patients with septic shock in a controlled, prospective study focusing on the organ functions of the patients.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
30

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Sep 2016

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2016

Completed
2 days until next milestone

First Submitted

Initial submission to the registry

September 3, 2016

Completed
17 days until next milestone

First Posted

Study publicly available on registry

September 20, 2016

Completed
5.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2022

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2022

Completed
Last Updated

April 7, 2020

Status Verified

April 1, 2020

Enrollment Period

5.6 years

First QC Date

September 3, 2016

Last Update Submit

April 4, 2020

Conditions

Keywords

Septic shockFresh frozen plasma

Outcome Measures

Primary Outcomes (2)

  • SOFA score ≥ 2 Punkte

    SOFA: Sepsis-related Organ Failure Assessment score

    day 3

  • SOFA score ≥ 2 Punkte

    SOFA: Sepsis-related Organ Failure Assessment score

    day 7

Secondary Outcomes (2)

  • 28-day survival

    day 28

  • Hospital survival

    1 year

Other Outcomes (2)

  • number of thrombocytes (DIC)

    days 1-7, 14, 21, 28

  • Haptoglobulin values

    days 1-7, 14, 21, 28

Study Arms (3)

Control Group

NO INTERVENTION

Patients with septic shock, no therapeutic plasma exchange, BMC standard treatment

TPE-Filtration Group

ACTIVE COMPARATOR

Patients with septic shock, therapeutic plasma exchange, plasma separation using a filter (Fresenius MultiFiltrate, Kit 16 MPS P2 dry), BMC standard treatment

Device: Therapeutic Plasma Exchange (TPE)

TPE-Centrifugation

ACTIVE COMPARATOR

Patients with septic shock, therapeutic plasma exchange, plasma separation using a centrifuge (Fresenius COM-TEC, PL1 Erythrozytapherese/Plasmabeutel Set) BMC standard treatment

Device: Therapeutic Plasma Exchange (TPE)

Interventions

All treated patients should treated two (minimal) to five times by TPE, depending on the need of norephinephrine for the therapy. For each session 40 ml/kg body weight plasma should be exchange. Fluid resuscitation will be done with fresh frozen plasma.

TPE-CentrifugationTPE-Filtration Group

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Septic shock, beginning of shock \< 24 hours

You may not qualify if:

  • Participation in an another clinical trial within the last 30 days
  • Participation in this study at an earlier date
  • Simultaneous participation in another clinical trial
  • Pregnancy
  • Unpredictable Bleeding (over 2 erythrocyte concentrates daily)
  • Polyneuropathy (known before the beginning of sepsis)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Intensive Care Units PIT 1+2, University Hospital Rostock

Rostock, 18055, Germany

RECRUITING

MeSH Terms

Conditions

Multiple Organ FailureShock, Septic

Interventions

Plasma Exchange

Condition Hierarchy (Ancestors)

ShockPathologic ProcessesPathological Conditions, Signs and SymptomsSepsisInfectionsSystemic Inflammatory Response SyndromeInflammation

Intervention Hierarchy (Ancestors)

Blood TransfusionBiological TherapyTherapeuticsPlasmapheresisBlood Component RemovalSorption DetoxificationExtracorporeal CirculationSurgical Procedures, Operative

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
PD Dr. med. habil.; MD

Study Record Dates

First Submitted

September 3, 2016

First Posted

September 20, 2016

Study Start

September 1, 2016

Primary Completion

April 1, 2022

Study Completion

August 1, 2022

Last Updated

April 7, 2020

Record last verified: 2020-04

Data Sharing

IPD Sharing
Will not share

No.

Locations